Ipamorelin/Tesamorelin 10mg

Dragon Pharma Ipamorelin/Tesamorelin 10mg is a pharmaceutical-grade dual-peptide combination vial delivering two of the most clinically researched growth hormone-optimizing compounds in a single, convenient research format. By combining Tesamorelin peptide— a synthetic GHRH analog that directly stimulates pituitary GH release for targeted visceral fat reduction — with Ipamorelin peptide— a selective ghrelin receptor agonist delivering controlled, cortisol-neutral GH pulsatility — this combination addresses both primary axes of natural GH secretion simultaneously.

Where each peptide excels individually, the combination eliminates the need to choose between targeted fat loss and clean recovery-focused GH optimization — delivering the full spectrum of growth hormone research benefits within a single protocol. For a detailed breakdown of how each compound performs independently, see our Ipamorelin vs Tesamorelin comparison.

Understanding the Dual Mechanism

The research value of Dragon Pharma Ipamorelin/Tesamorelin 10mg lies in the mechanistic complementarity of its two components — they target entirely separate receptor pathways to stimulate GH release, creating non-redundant, additive effects that neither compound achieves alone.

Tesamorelin — GHRH Receptor Pathway

• Classification: Synthetic GHRH analog
• Mechanism: Binds GHRH receptors on the anterior pituitary, directly mimicking endogenous GHRH to trigger pulsatile GH secretion
• Primary research target: Visceral adipose tissue (VAT) reduction, IGF-1 elevation exceeding 180% from baseline, lean mass preservation during caloric deficits
• Additional benefit: Emerging cognitive research suggests improvements in memory, executive function, and mental clarity through GH-driven neuroprotective mechanisms

Ipamorelin — GHS-R1a Receptor Pathway

• Classification: Selective ghrelin mimetic / GH secretagogue
• Mechanism: Binds growth hormone secretagogue receptor (GHS-R1a), mimicking ghrelin to prompt gradual, controlled GH release from the pituitary
• Primary research target: Sleep architecture improvement, slow-wave sleep enhancement, muscle recovery, tissue regeneration
• Key differentiator: Completely cortisol and prolactin neutral — no adrenal axis stimulation, no endocrine disruption at any standard research dose

Combined Dual-Axis Effect

Tesamorelin increases GH pulse amplitude via GHRH receptors; Ipamorelin increases GH pulse frequency via GHS-R1a receptors. Together they replicate complete physiologic pulsatile GH secretion — the same pattern the body uses naturally — delivering greater total GH output, superior fat loss, enhanced lean mass support, and improved recovery versus either compound researched in isolation.

Dragon Pharma Ipamorelin/Tesamorelin 10mg — Combined Research Benefits

• Targeted visceral fat reduction — Tesamorelin's clinically validated VAT reduction addresses stubborn abdominal fat resistant to conventional diet and cardio interventions, improving waist circumference, metabolic health, and cardiometabolic risk profile
• Lean muscle preservation and development — combined IGF-1 elevation from both peptides amplifies protein synthesis signaling, protecting lean tissue during caloric deficits and supporting hypertrophy in resistance training research
• Optimized sleep architecture — Ipamorelin's slow-wave sleep enhancement maximizes overnight GH secretion, muscle repair, hormonal balance, and cognitive restoration — compounding Tesamorelin's daytime metabolic benefits into a 24-hour recovery cycle
• Cognitive function support — Tesamorelin's neuroprotective GH mechanisms improve memory and executive function while Ipamorelin's sleep architecture benefits support overnight cognitive restoration — a dual approach to neurological recovery research
• Complete GH axis optimization — GHRH receptor stimulation combined with GHS-R1a activation covers both primary pathways of natural pituitary GH release, delivering the most complete endogenous GH optimization available in a single research vial
• Hormonal environment preservation — Ipamorelin's cortisol and prolactin neutrality offsets any mild adrenal signals from Tesamorelin, maintaining a clean anabolic hormonal environment throughout the protocol

Dosage Guide — Dragon Pharma Ipamorelin/Tesamorelin 10mg

The combination vial format simplifies dual-peptide research protocols — eliminating separate reconstitution, separate vial management, and complex dosing calculations. Individual component dosing reflects established research ranges for each peptide:

Administration notes:

• Administer via subcutaneous injection — abdomen or thigh; rotate injection sites to prevent tissue irritation
• Evening/bedtime dosing is optimal for both components — aligning GHRH-driven GH stimulation and ghrelin receptor activation with the body's largest natural nocturnal GH pulse during slow-wave sleep
• Tesamorelin requires strict daily consistency — results are highly dependent on uninterrupted dosing schedules; Ipamorelin offers greater flexibility for split AM/PM protocols in active research subjects
• Reconstitute with bacteriostatic water under sterile conditions; store reconstituted vials refrigerated and protect from light

Research Cycle Length and Results Timeline

• Minimum effective cycle: 8 weeks for measurable IGF-1 elevation, initial VAT reduction, and sleep quality improvements
• Optimal research range: 8–12 weeks for significant body composition, fat loss, lean mass, and recovery outcomes
• Extended protocols: up to 12 months observed in clinical Tesamorelin populations with appropriate glucose monitoring

Combined outcome timeline:

• Weeks 2–4: Improved sleep depth and quality, faster training recovery, early IGF-1 elevation, reduced appetite fluctuation
• Weeks 4–8: Measurable visceral fat reduction, progressive body recomposition, enhanced metabolic flexibility, improved cognitive clarity
• Weeks 8–12+: Significant VAT reduction, confirmed lean mass preservation, joint and connective tissue recovery, sustained dual-axis GH optimization

Who Is This Research Protocol For?

Dragon Pharma Ipamorelin/Tesamorelin 10mg is the research protocol of choice when:

• Both fat loss and recovery are primary research objectives — eliminating the need to choose between Tesamorelin's metabolic fat-loss profile and Ipamorelin's recovery and sleep architecture benefits
• Maximum GH axis coverage is required — researchers studying complete pituitary GH optimization need both GHRH and GHS-R1a receptor pathways activated
• Body recomposition research — simultaneous visceral fat reduction and lean mass preservation is the defining challenge of recomposition protocols; the combination addresses both sides directly
• Anti-aging and longevity research — cognitive support, sleep architecture, tissue regeneration, and metabolic health optimization represent the core pillars of longevity peptide research; this combination covers all four
• Simplified dual-peptide logistics — single vial format eliminates the complexity of managing two separate peptide reconstitution and storage protocols

Side Effects and Safety Considerations

The combined side effect profile of Dragon Pharma Ipamorelin/Tesamorelin 10mg reflects the individual profiles of each component — with Ipamorelin's favorable tolerability partially offsetting Tesamorelin's moderate GH-related effects.

• Injection site reactions — redness, mild irritation, or swelling at the subcutaneous injection site; minimized by consistent site rotation between abdomen and thigh
• Water retention and mild edema — GH elevation-related subcutaneous fluid retention; most pronounced in the first 2–4 weeks of the combined protocol
• Joint and muscle pain — IGF-1 elevation from Tesamorelin's strong GH stimulation may produce musculoskeletal aches; managed by strict adherence to standard research dosing
• Glucose tolerance monitoring — Tesamorelin's mild impact on insulin sensitivity requires fasting blood glucose and HbA1c monitoring throughout the research protocol; particularly important for subjects with pre-existing metabolic conditions or insulin resistance
• Headache and dizziness — primarily Ipamorelin-associated; transient and resolving within the first 1–2 weeks of consistent dosing
• Carpal tunnel-like symptoms — tingling or numbness possible at elevated IGF-1 levels; resolved by dose management

Ipamorelin's cortisol and prolactin neutrality provides a stabilizing effect on the combined hormonal environment — preventing adrenal axis disruption that could otherwise compound Tesamorelin's moderate side effect profile.

Why Dragon Pharma Ipamorelin/Tesamorelin 10mg?

Dragon Pharma's pharmaceutical-grade manufacturing delivers both peptide blend components in a single verified vial — confirmed concentration, structural integrity, and consistent dual-receptor research activity across every batch.

• Verified combined 10mg peptide concentration per vial through independent third-party laboratory analysis
• Pharmaceutical-grade lyophilization preserving full bioactivity of both GHRH analog and ghrelin mimetic structural integrity
• The only dual-peptide GH optimization vial in the Dragon Pharma growth hormone peptide research line — combining the two most complementary GH pathways in a single research format